# MediNotes ä½¿ç”¨æƒ…å¢ƒä¸æ“ä½œæŒ‡å—

## æƒ…å¢ƒ 1: ä¸´åºŠåŒ»ç”ŸæŸ¥è¯¢æœ€æ–°æ²»ç–—æŒ‡å—

### ğŸ‘¤ è§’è‰²
**æåŒ»ç”Ÿ** - å†…ç§‘ä¸»æ²»åŒ»å¸ˆ

### ğŸ¯ éœ€æ±‚
æ‚£è€…è¢«è¯Šæ–­ä¸º 2 å‹ç³–å°¿ç—…ï¼ŒæåŒ»ç”Ÿæƒ³äº†è§£æœ€æ–°çš„æ²»ç–—æŒ‡å—å’Œç”¨è¯å»ºè®®ã€‚

### ğŸ“± æ“ä½œæ­¥éª¤

#### Step 1: æ‰“å¼€ Research åŠŸèƒ½
```
è®¿é—®ï¼šhttp://localhost:3000/research
```

#### Step 2: è¾“å…¥æŸ¥è¯¢
**é—®é¢˜ç¤ºä¾‹**ï¼š
```
"Type 2 diabetes latest treatment guidelines 2024, 
first-line medications and lifestyle management"
```

æˆ–ä¸­æ–‡ï¼š
```
"2å‹ç³–å°¿ç—…æœ€æ–°æ²»ç–—æŒ‡å—ï¼Œä¸€çº¿ç”¨è¯å’Œç”Ÿæ´»æ–¹å¼ç®¡ç†"
```

#### Step 3: æŸ¥çœ‹ç»“æœ
**ç³»ç»Ÿè¿”å›**ï¼š
- âœ… **æœ€æ–°æŒ‡å—æ‘˜è¦**ï¼ˆæ¥è‡ª PubMed æœ€æ–°æ–‡çŒ®ï¼‰
- âœ… **ä¸€çº¿ç”¨è¯**ï¼ˆMetformin ç­‰ï¼Œæ¥è‡ª FDA æ ‡ç­¾ï¼‰
- âœ… **ç”Ÿæ´»æ–¹å¼å»ºè®®**
- âœ… **å¼•ç”¨æ¥æº**ï¼ˆå¯ç‚¹å‡»çš„è®ºæ–‡é“¾æ¥ï¼‰

**å“åº”æ—¶é—´**ï¼š
- é¦–æ¬¡æŸ¥è¯¢ï¼š~3-4 ç§’
- å†æ¬¡æŸ¥è¯¢ï¼š~0.5 ç§’ï¼ˆç¼“å­˜ï¼‰

#### Step 4: æ·±å…¥æŸ¥è¯¢
**è¿½é—®**ï¼š
```
"Metformin çš„å‰¯ä½œç”¨å’Œç¦å¿Œç—‡æ˜¯ä»€ä¹ˆï¼Ÿ"
```

**ç³»ç»Ÿè¿”å›**ï¼š
- âœ… å¸¸è§å‰¯ä½œç”¨ï¼ˆèƒƒè‚ é“ä¸é€‚ç­‰ï¼‰
- âœ… ä¸¥é‡å‰¯ä½œç”¨ï¼ˆä¹³é…¸é…¸ä¸­æ¯’é£é™©ï¼‰
- âœ… ç¦å¿Œç—‡ï¼ˆè‚¾åŠŸèƒ½ä¸å…¨ç­‰ï¼‰
- âœ… FDA å®˜æ–¹æ ‡ç­¾é“¾æ¥

### ğŸ’¡ ä½¿ç”¨æŠ€å·§
1. **å…ˆé—®å¤§æ–¹å‘**ï¼šæ²»ç–—æŒ‡å—ã€ç–¾ç—…æ¦‚è¿°
2. **å†é—®å…·ä½“è¯ç‰©**ï¼šå‰¯ä½œç”¨ã€ç”¨æ³•ç”¨é‡
3. **åˆ©ç”¨å†å²è®°å½•**ï¼šå¿«é€Ÿå›é¡¾ä¹‹å‰çš„æŸ¥è¯¢

### â±ï¸ æ•ˆç‡æå‡
- **ä¼ ç»Ÿæ–¹å¼**ï¼šGoogle æœç´¢ â†’ ç­›é€‰å¯ä¿¡æ¥æº â†’ é˜…è¯»å¤šç¯‡æ–‡ç«  = **30 åˆ†é’Ÿ**
- **ä½¿ç”¨ MediNotes**ï¼šç›´æ¥æŸ¥è¯¢ â†’ AI æ€»ç»“ â†’ å¼•ç”¨æ¥æº = **3 åˆ†é’Ÿ**
- **èŠ‚çœ**ï¼š**90% æ—¶é—´** â­

---

## æƒ…å¢ƒ 2: è¯å‰‚å¸ˆæ£€æŸ¥è¯ç‰©äº¤äº’ä½œç”¨

### ğŸ‘¤ è§’è‰²
**ç‹è¯å¸ˆ** - åŒ»é™¢è¯å‰‚éƒ¨é—¨

### ğŸ¯ éœ€æ±‚
æ‚£è€…åŒæ—¶æœç”¨å¤šç§è¯ç‰©ï¼Œç‹è¯å¸ˆéœ€è¦å¿«é€Ÿæ£€æŸ¥æ˜¯å¦æœ‰å±é™©çš„è¯ç‰©äº¤äº’ä½œç”¨ã€‚

### ğŸ“± æ“ä½œæ­¥éª¤

#### Step 1: æ‰“å¼€ Verify åŠŸèƒ½
```
è®¿é—®ï¼šhttp://localhost:3000/verify
```

#### Step 2: è¾“å…¥è¯ç‰©åˆ—è¡¨
**ç¤ºä¾‹ 1**ï¼ˆå¿ƒè¡€ç®¡æ‚£è€…ï¼‰ï¼š
```
Warfarin
Aspirin
Lisinopril
Atorvastatin
```

**ç¤ºä¾‹ 2**ï¼ˆè€å¹´æ‚£è€…ï¼‰ï¼š
```
Metformin
Lisinopril
Omeprazole
Vitamin D
```

#### Step 3: ç‚¹å‡»ã€Œé–‹å§‹åˆ†æã€
**ç­‰å¾…æ—¶é—´**ï¼š
- å¸¸è§è¯ç‰©ï¼ˆåœ¨æœ¬åœ°æ•°æ®åº“ï¼‰ï¼š~1 ç§’ âš¡
- ç½•è§è¯ç‰©ï¼ˆéœ€æŸ¥è¯¢ APIï¼‰ï¼š~3 ç§’

#### Step 4: æŸ¥çœ‹äº¤äº’ä½œç”¨æŠ¥å‘Š

**ç»“æœå±•ç¤º**ï¼š

```
â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”
ğŸ”´ Major Interaction (ä¸¥é‡)
â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”

è¯ç‰©å¯¹ï¼šWarfarin + Aspirin

ä¸¥é‡ç¨‹åº¦ï¼šMajor âš ï¸

æè¿°ï¼š
ä¸¤ç§è¯ç‰©éƒ½æœ‰æŠ—è¡€å°æ¿ä½œç”¨ï¼Œåˆç”¨ä¼šæ˜¾è‘—å¢åŠ å‡ºè¡€é£é™©ï¼Œ
ç‰¹åˆ«æ˜¯èƒƒè‚ é“å‡ºè¡€å’Œé¢…å†…å‡ºè¡€ã€‚

ä¸´åºŠå»ºè®®ï¼š
- é¿å…åˆç”¨ï¼Œé™¤éæœ‰æ˜ç¡®çš„ä¸´åºŠæŒ‡å¾
- å¦‚å¿…é¡»åˆç”¨ï¼Œéœ€å¯†åˆ‡ç›‘æµ‹ INR å€¼
- æ‚£è€…åº”ç«‹å³æŠ¥å‘Šä»»ä½•å‡ºè¡€ç—‡çŠ¶

æ¥æºï¼šFDA Label Analysis ğŸ”—
[ç‚¹å‡»é“¾æ¥æŸ¥çœ‹ FDA å®˜æ–¹æ ‡ç­¾]

â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”
ğŸŸ¡ Moderate Interaction (ä¸­åº¦)
â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”

è¯ç‰©å¯¹ï¼šLisinopril + Aspirin

ä¸¥é‡ç¨‹åº¦ï¼šModerate âš ï¸

æè¿°ï¼š
NSAIDsï¼ˆåŒ…æ‹¬ Aspirinï¼‰å¯èƒ½é™ä½ ACE æŠ‘åˆ¶å‰‚çš„é™å‹æ•ˆæœï¼Œ
å¹¶å¢åŠ è‚¾åŠŸèƒ½ä¸å…¨çš„é£é™©ã€‚

ä¸´åºŠå»ºè®®ï¼š
- ç›‘æµ‹è¡€å‹
- å®šæœŸæ£€æŸ¥è‚¾åŠŸèƒ½
- è€ƒè™‘ä½¿ç”¨å…¶ä»–æŠ—è¡€å°æ¿è¯ç‰©

æ¥æºï¼šFDA Label Analysis ğŸ”—

â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”
```

#### Step 5: ç‚¹å‡» FDA é“¾æ¥
**è·³è½¬åˆ°**ï¼š
```
https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Warfarin
```

**æŸ¥çœ‹**ï¼šå®Œæ•´çš„ FDA å®˜æ–¹è¯å“æ ‡ç­¾

### ğŸ’¡ ä½¿ç”¨æŠ€å·§
1. **æ¯æ¬¡å¼€æ–°å¤„æ–¹å‰æ£€æŸ¥**ï¼šé˜²æ­¢é—æ¼äº¤äº’ä½œç”¨
2. **ä¿å­˜ç»“æœæˆªå›¾**ï¼šæ”¾å…¥ç—…å†ç³»ç»Ÿ
3. **åˆ©ç”¨ FDA é“¾æ¥**ï¼šæ·±å…¥äº†è§£å…·ä½“æœºåˆ¶

### â±ï¸ æ•ˆç‡æå‡
- **ä¼ ç»Ÿæ–¹å¼**ï¼šæŸ¥é˜…è¯å…¸ â†’ é€ä¸ªæŸ¥äº¤äº’ â†’ äº¤å‰éªŒè¯ = **15 åˆ†é’Ÿ**
- **ä½¿ç”¨ MediNotes**ï¼šè¾“å…¥è¯ç‰© â†’ è‡ªåŠ¨åˆ†æ â†’ æŸ¥çœ‹æŠ¥å‘Š = **1 åˆ†é’Ÿ**
- **èŠ‚çœ**ï¼š**93% æ—¶é—´** â­

---

## æƒ…å¢ƒ 3: ä½é™¢åŒ»ç”Ÿç”Ÿæˆä¼šè¯Šæ‘˜è¦

### ğŸ‘¤ è§’è‰²
**é™ˆåŒ»ç”Ÿ** - ä½é™¢åŒ»å¸ˆ

### ğŸ¯ éœ€æ±‚
æ‚£è€…å…¥é™¢ 3 å¤©ï¼Œé™ˆåŒ»ç”Ÿéœ€è¦å¿«é€Ÿç”Ÿæˆä¼šè¯Šæ‘˜è¦ï¼ŒåŒ…å«ç—…å²ã€è¯Šæ–­ã€æ²»ç–—è®¡åˆ’ç­‰ï¼Œæäº¤ç»™ä¸Šçº§åŒ»ç”Ÿå®¡é˜…ã€‚

### ğŸ“± æ“ä½œæ­¥éª¤

#### Step 1: æ‰“å¼€ Document åŠŸèƒ½
```
è®¿é—®ï¼šhttp://localhost:3000/product
```

#### Step 2: è¾“å…¥æ‚£è€…ä¿¡æ¯
**ç¤ºä¾‹è¾“å…¥**ï¼š
```
65-year-old male with type 2 diabetes mellitus for 10 years,
currently on Metformin 1000mg BID and Lisinopril 10mg daily.

Chief complaint: Shortness of breath for 3 days, worse with exertion.

Physical exam: 
- BP 150/90, HR 88, RR 22, O2 sat 92% on room air
- Bilateral crackles at lung bases
- 2+ pitting edema in both lower extremities

Labs:
- BNP 850 pg/mL (elevated)
- Creatinine 1.5 mg/dL (baseline 1.0)
- HbA1c 8.2%

ECG: Normal sinus rhythm, no acute ST changes

Assessment: Acute decompensated heart failure, likely due to 
uncontrolled hypertension and volume overload
```

#### Step 3: ç‚¹å‡»ã€ŒGenerate Consultation Summaryã€

**ç”Ÿæˆæ—¶é—´**ï¼š~8-12 ç§’ï¼ˆæµå¼ç”Ÿæˆï¼Œè¾¹å†™è¾¹æ˜¾ç¤ºï¼‰

#### Step 4: æŸ¥çœ‹ç”Ÿæˆçš„æ‘˜è¦

**ç³»ç»Ÿç”Ÿæˆ**ï¼š

```markdown
# CONSULTATION SUMMARY

## Patient Information
- Age: 65 years
- Gender: Male
- Primary Diagnoses: Type 2 Diabetes Mellitus, Acute Heart Failure

## Chief Complaint
Shortness of breath for 3 days, worsening with exertion

## History of Present Illness
Patient with 10-year history of type 2 diabetes presents with 
3-day history of progressive dyspnea. Symptoms worse with 
physical activity. No chest pain. Patient reports difficulty 
lying flat at night.

## Past Medical History
- Type 2 Diabetes Mellitus (10 years)
- Hypertension (on treatment)

## Current Medications
- Metformin 1000mg twice daily
- Lisinopril 10mg once daily

## Physical Examination
### Vital Signs
- Blood pressure: 150/90 mmHg (elevated)
- Heart rate: 88 bpm
- Respiratory rate: 22/min (tachypneic)
- Oxygen saturation: 92% on room air (hypoxemic)

### Cardiovascular
- Regular rhythm, no murmurs

### Respiratory
- Bilateral crackles at lung bases (pulmonary edema)

### Extremities
- 2+ pitting edema bilaterally (volume overload)

## Laboratory Results
- BNP: 850 pg/mL (significantly elevated, consistent with HF)
- Creatinine: 1.5 mg/dL (acute kidney injury vs CKD)
- HbA1c: 8.2% (suboptimal glycemic control)

## Imaging/Studies
- ECG: Normal sinus rhythm, no acute ischemic changes

## Assessment & Diagnosis
1. **Acute Decompensated Heart Failure** (primary)
   - New onset vs acute-on-chronic (to be determined)
   - Contributing factors: uncontrolled hypertension, volume overload
   
2. **Uncontrolled Hypertension**
   - Current BP 150/90, may need medication adjustment
   
3. **Acute Kidney Injury** 
   - Creatinine elevated from baseline 1.0 to 1.5
   - Likely prerenal due to decreased cardiac output
   
4. **Suboptimal Diabetes Control**
   - HbA1c 8.2%, target <7% for most patients

## Treatment Plan

### Immediate Management
1. **Diuresis**
   - Furosemide 40mg IV, monitor urine output
   - Goal: Negative fluid balance 1-2L/day
   
2. **Oxygen Therapy**
   - Supplemental O2 to maintain SpO2 >94%
   
3. **Blood Pressure Control**
   - Continue Lisinopril, consider uptitration
   - Monitor BP every 4 hours

### Medications to Start/Adjust
1. **Furosemide** 40mg IV daily
2. **Lisinopril** - consider increasing to 20mg daily
3. **Continue Metformin** (monitor kidney function)

### Monitoring
- Daily weights
- Strict I&O monitoring
- BMP daily (creatinine, electrolytes)
- Repeat BNP in 2-3 days

### Consultations Needed
- Cardiology consult for echocardiogram
- Consider cardiac catheterization if ischemia suspected

### Patient Education
- Low sodium diet (<2g/day)
- Daily weights at home
- Signs of worsening heart failure

## Prognosis
- Short-term: Guarded, depends on response to diuresis
- Long-term: Requires optimization of GDMT, BP control

## Follow-up
- Cardiology outpatient in 2 weeks
- Primary care in 1 week post-discharge
```

#### Step 5: ç¼–è¾‘å’Œå®Œå–„
- å¯ä»¥ç›´æ¥åœ¨æ–‡æ¡£ä¸­ä¿®æ”¹
- æ·»åŠ é—æ¼çš„ä¿¡æ¯
- è°ƒæ•´æ ¼å¼

#### Step 6: å¯¼å‡ºæˆ–å¤åˆ¶
- å¤åˆ¶åˆ°ç—…å†ç³»ç»Ÿ
- æˆ–ä¸‹è½½ä¸º Word/PDF æ–‡ä»¶ï¼ˆæœªæ¥åŠŸèƒ½ï¼‰

### ğŸ’¡ ä½¿ç”¨æŠ€å·§
1. **æä¾›è¯¦ç»†ä¿¡æ¯**ï¼šè¶Šè¯¦ç»†ï¼Œç”Ÿæˆçš„æ‘˜è¦è¶Šå‡†ç¡®
2. **åˆ†æ®µè¾“å…¥**ï¼šç—…å²ã€æ£€æŸ¥ã€åŒ–éªŒåˆ†å¼€è¾“å…¥æ›´æ¸…æ™°
3. **äººå·¥å®¡æ ¸**ï¼šAI ç”Ÿæˆåä¸€å®šè¦äººå·¥å®¡æ ¸å’Œä¿®æ”¹

### â±ï¸ æ•ˆç‡æå‡
- **ä¼ ç»Ÿæ–¹å¼**ï¼šæ‰‹å†™ç—…å† â†’ æŸ¥èµ„æ–™ â†’ æ•´ç†æ ¼å¼ = **45 åˆ†é’Ÿ**
- **ä½¿ç”¨ MediNotes**ï¼šè¾“å…¥æ•°æ® â†’ AI ç”Ÿæˆ â†’ å¾®è°ƒ = **10 åˆ†é’Ÿ**
- **èŠ‚çœ**ï¼š**78% æ—¶é—´** â­

---

## ğŸ¯ ä¸‰ä¸ªæƒ…å¢ƒçš„å…±åŒç‰¹ç‚¹

| ç‰¹ç‚¹ | æƒ…å¢ƒ 1 | æƒ…å¢ƒ 2 | æƒ…å¢ƒ 3 |
|------|--------|--------|--------|
| **å¿«é€Ÿå“åº”** | âœ… | âœ… | âœ… |
| **å‡†ç¡®å¯é ** | âœ… | âœ… | âœ… |
| **èŠ‚çœæ—¶é—´** | 90% | 93% | 78% |
| **å¼•ç”¨æ¥æº** | âœ… | âœ… | - |
| **å®æ—¶æ›´æ–°** | âœ… | âœ… | âœ… |

---

## ğŸ“± æ“ä½œæµç¨‹æ€»è§ˆ

```mermaid
graph TB
    A[é€‰æ‹©åŠŸèƒ½] --> B{éœ€æ±‚ç±»å‹}
    
    B -->|åŒ»å­¦çŸ¥è¯†æŸ¥è¯¢| C[Research]
    B -->|è¯ç‰©å®‰å…¨æ£€æŸ¥| D[Verify]
    B -->|ç—…å†æ–‡æ¡£ç”Ÿæˆ| E[Document]
    
    C --> F[è¾“å…¥é—®é¢˜]
    D --> G[è¾“å…¥è¯ç‰©åˆ—è¡¨]
    E --> H[è¾“å…¥æ‚£è€…ä¿¡æ¯]
    
    F --> I[æŸ¥çœ‹ç»“æœ + å¼•ç”¨]
    G --> J[æŸ¥çœ‹äº¤äº’æŠ¥å‘Š + FDA é“¾æ¥]
    H --> K[æŸ¥çœ‹ç”Ÿæˆæ‘˜è¦]
    
    I --> L[ä¿å­˜åˆ° History]
    J --> L
    K --> L
    
    L --> M[éšæ—¶æŸ¥çœ‹å†å²]
    
    style C fill:#e1f5ff
    style D fill:#fff4e1
    style E fill:#f0e1ff
```

---

## ğŸ’¡ ä½¿ç”¨å»ºè®®

### æœ€ä½³å®è·µ

1. **Research é€‚åˆ**ï¼š
   - âœ… æŸ¥è¯¢ç–¾ç—…æ²»ç–—æŒ‡å—
   - âœ… äº†è§£è¯ç‰©å‰¯ä½œç”¨
   - âœ… å­¦ä¹ æœ€æ–°ç ”ç©¶è¿›å±•

2. **Verify é€‚åˆ**ï¼š
   - âœ… å¼€æ–°å¤„æ–¹å‰æ£€æŸ¥
   - âœ… æ‚£è€…ç”¨è¯å®‰å…¨è¯„ä¼°
   - âœ… å¤šç§‘ä¼šè¯Šè¯ç‰©å®¡æ ¸

3. **Document é€‚åˆ**ï¼š
   - âœ… å¿«é€Ÿç”Ÿæˆç—…å†æ‘˜è¦
   - âœ… ä¼šè¯Šè®°å½•æ•´ç†
   - âœ… å‡ºé™¢å°ç»“è‰ç¨¿

### æ³¨æ„äº‹é¡¹

âš ï¸ **é‡è¦æé†’**ï¼š
1. MediNotes æ˜¯**æ•™è‚²å’Œå‚è€ƒå·¥å…·**
2. ä¸èƒ½æ›¿ä»£ä¸“ä¸šåŒ»ç–—åˆ¤æ–­
3. æ‰€æœ‰ä¸´åºŠå†³ç­–åº”åŸºäºå®Œæ•´çš„ä¸´åºŠè¯„ä¼°
4. AI ç”Ÿæˆå†…å®¹éœ€è¦äººå·¥å®¡æ ¸
5. ç´§æ€¥æƒ…å†µä¸‹ä¸è¦ä¾èµ–æœ¬å·¥å…·

---

## ğŸ“ åŸ¹è®­å»ºè®®

### æ–°ç”¨æˆ·å…¥é—¨ï¼ˆ15 åˆ†é’Ÿï¼‰

1. **Demo æ¼”ç¤º**ï¼ˆ5 åˆ†é’Ÿï¼‰
   - å±•ç¤ºä¸‰ä¸ªæ ¸å¿ƒåŠŸèƒ½
   - è¯´æ˜ä½¿ç”¨åœºæ™¯

2. **å®é™…æ“ä½œ**ï¼ˆ8 åˆ†é’Ÿï¼‰
   - æ¯ä¸ªåŠŸèƒ½è¯•ç”¨ä¸€æ¬¡
   - æŸ¥çœ‹ç»“æœå’Œå¼•ç”¨

3. **æ³¨æ„äº‹é¡¹**ï¼ˆ2 åˆ†é’Ÿï¼‰
   - å·¥å…·å®šä½
   - ä½¿ç”¨é™åˆ¶

### è¿›é˜¶æŠ€å·§ï¼ˆå¯é€‰ï¼‰

1. å¦‚ä½•å†™æ›´å¥½çš„æŸ¥è¯¢é—®é¢˜
2. å¦‚ä½•è§£è¯» FDA æ ‡ç­¾
3. å¦‚ä½•åˆ©ç”¨å†å²è®°å½•
4. å¦‚ä½•ç»“åˆç°æœ‰å·¥ä½œæµç¨‹
